Abstract: Tissue access devices and methods of using the same are disclosed. The devices can have a sensor configured to occlude a flow path by deflecting a membrane into the flow path when the devices become dislodged from tissue. The sensor can be configured to partially or fully occlude the flow path. The sensor can have a spring. The spring can be biased to move the sensor from a sensor first configuration to a sensor second configuration when a force applied by the sensor first surface against a non-sensor surface changes from a first force to a second force less than the first force. The membrane can be deflected into the flow path when the sensor is in the sensor second configuration.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: An airfoil cooling system (54) for a gas turbine engine (10) is disclosed. The airfoil cooling system (54) may be formed from at least a first cooling fluid supply system (56), and a second cooling fluid supply system (58). The first cooling fluid supply system (56) may be configured to supply cooling fluids at a first pressure to one or more airfoils of a first row (68) of airfoils, and the second cooling fluid supply system (58) may be configured to supply cooling fluids at a second pressure to the one or more airfoils of the first row (68) of airfoils. Additionally, the second pressure may be lower than the first pressure. As such, each of the one or more airfoils may be cooled by cooling fluids at two different pressures. In particular embodiments, this may allow the airfoils to be cooled, while lowering the cost to the turbine engine (10) for providing such cooling.

Abstract: A turbine airfoil cooling system including a low pressure cooling system and a high pressure cooling system for a turbine airfoil of a gas turbine engine is disclosed. In at least one embodiment, the low pressure cooling system may be an ambient air cooling system, and the high pressure cooling system may be a compressor bleed air cooling system. In at least one embodiment, the compressor bleed air cooling system in communication with a high pressure subsystem that may be a snubber cooling system positioned within a snubber. A delivery system including a movable air supply tube may be used to separate the low and high pressure cooling subsystems. The delivery system may enable high pressure cooling air to be passed to the snubber cooling system separate from low pressure cooling fluid supplied by the low pressure cooling system to other portions of the turbine airfoil cooling system.

Abstract: A turbine airfoil assembly for installation in a gas turbine engine. The airfoil assembly includes an endwall and an airfoil extending radially outwardly from the endwall. The airfoil includes pressure and suction sidewalls defining chordally spaced apart leading and trailing edges of the airfoil. An airfoil mean line is defined located centrally between the pressure and suction sidewalls. An angle between the mean line and a line parallel to the engine axis at the leading and trailing edges defines gas flow entry angles, ?, and exit angles, ?. Airfoil inlet and exit angles are substantially in accordance with inlet angle values, ?, and exit angle values, ?, set forth in one of Tables 1, 2, 3, and 4.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Abstract: A turbine airfoil usable in a turbine engine and having at least one snubber with a snubber cooling system positioned therein and in communication with an airfoil cooling system is disclosed. The snubber may extend from the outer housing of the airfoil toward an adjacent turbine airfoil positioned within a row of airfoils. The snubber cooling system may include an inner cooling channel separated from an outer cooling channel by an inner wall. The inner wall may include a plurality of impingement cooling orifices that direct impingement fluid against an outer wall defining the outer cooling channel. In one embodiment, the cooling fluids may be exhausted from the snubber, and in another embodiment, the cooling fluids may be returned to the airfoil cooling system. Flow guides may be positioned in the outer cooling channel, which may reduce cross-flow by the impingement orifices, thereby increasing effectiveness.

Abstract: A turbine airfoil assembly for installation in a gas turbine engine. The airfoil assembly includes an endwall and an airfoil extending radially outwardly from the endwall. The airfoil includes pressure and suction sidewalls defining chordally spaced apart leading and trailing edges of the airfoil. An airfoil mean line is defined located centrally between the pressure and suction sidewalls. An angle between the mean line and a line parallel to the engine axis at the leading and trailing edges defines gas flow entry angles, ?, and exit angles, ?. Airfoil inlet and exit angles are substantially in accordance with inlet angle values, ?, and exit angle values, ?, set forth in one of Tables 1, 2, 3, and 4.